News & Media

Press release
Updated interim phase IIa data demonstrate that the combination of simeprevir, odalasvir and AL-335 has a high level of efficacy in HCV patients

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that updated interim data from a phase IIa study being conducted...

Read more
Press release
MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead based on independent review of safety data, and first patient enrolled in extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces new information about its phase IIa program for the treatment of...

Read more
Press release
Interim results from phase IIa trial evaluating triple combination including simeprevir demonstrates high level of efficacy in HCV patients

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that interim results from a phase IIa study being conducted by...

Read more
Press release
Medivir proceeds with a separation of the company’s operations

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has tasked the company management to...

Read more
Press release
Medivir licenses rights to MIV-802 to Trek Therapeutics

Stockholm/Cambridge, Massachusetts — Medivir AB (Nasdaq Stockholm: MVIR) and Trek Therapeutics (TREKtx) today announced that TREKtx has licensed the exclusive rights...

Read more
Press release
MEDIVIR AB – INTERIM REPORT, JANUARY – JUNE 2016

Financial summary Second quarter 2016 Net turnover totalled SEK 81.3 million (245.8 m), of which SEK 24.2 million (165.6 m) comprised...

Read more
Press release
New interim phase IIa data on simeprevir in combination with other DAAs will be presented at the upcoming EASL AASLD Special Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data from an ongoing phase IIa study of...

Read more
Press release
Medivir investigates possible corporate split and separate listing of commercial operations

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has tasked the company management with...

Read more
Press release
Medivir announces that Janssen decided to start a phase IIb study of combinations of Simeprevir, Odalasvir and AL-335 for the treatment of hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Research & Development, LLC., part of the Janssen Pharmaceutical...

Read more
Press release
Resolutions at the annual general meeting in Medivir on 3 May 2016

Election of the board of directors and auditorThe annual general meeting in Medivir Aktiebolag (publ) on 3 May 2016 resolved, in...

Read more
Press release
MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2016

Financial summary for the first quarter Net turnover totalled SEK 75.0 million (215.9 m), of which SEK 18.1 million (128.6 m)...

Read more
Press release
OLYSIO® sales during the first quarter 2016

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted...

Read more